Clinical Trial

Global Alzheimer’s Platform Foundation Announces Strategic Collaboration and Partnership with Siemens Healthineers for the Transformative Bio-Hermes-002 Study

Siemens Healthineers joins collaborative study focused on new biomarkers designed to improve diagnosis of Alzheimer's disease and dementiasWASHINGTON, April 09,...

Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC

CEO Abizer Gaslightwala discusses the Company’s strategic partnership with WuXi XDC and its implications for platform validation and development acceleration...

Onconetix Highlights Realbotix’s Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to Ericsson

Vinci Enables Realbotix Robots to Recognize People, Recall Conversations, and Track Engagement; Onconetix Recently Entered into a Definitive Agreement to...

Sparian Biosciences Announces Initiation of Phase 1 Clinical Trial of SBS-147 Next Generation Arylepoxamide Agonist for the Treatment of Pain Funded by a $15M NIH Grant

Phase 1 clinical trial will evaluate the safety, tolerability, and pharmacokineticsSBS-147 is a novel and potent oral analgesic with a...

NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer’s and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit

SANTA ANA, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage...

Washington’s Hemp Shell Game: How Medicare Dollars Are Funding Non-Approved Products While FDA-Compliant Medicines Wait

"As CMS Launches its $500 Cannabinoid "Engagement Incentive," MMJ International Holdings Warns of a Regulatory "Double Standard" That Rewards Loophole-Navigators...

ProofPilot Announces 2nd CORE Symposium, Gathering Pharma and Biotech Leaders to Tackle Clinical Operations’ Toughest Challenges

BOSTON, April 8, 2026 /PRNewswire/ -- ProofPilot, the platform purpose-built to make clinical trials simple and predictable for study stakeholders, today...

error: Content is protected !!